← Back to Search

ReActiv8 Neurostimulation for Chronic Lower Back Pain (ReActiv8-B Trial)

N/A
Waitlist Available
Research Sponsored by Mainstay Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥22 years, ≤75 years
Be older than 18 years old
Must not have
Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or lumbar annular tear with disc protrusion that is amenable to surgery
Back pain due to vascular causes such as aortic aneurysm and dissection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing ReActiv8, a device that helps reduce chronic low back pain by stimulating muscles in the lower back. It is aimed at adults who have long-term back pain that isn't fully managed by regular treatments. The device works by sending electrical signals to strengthen the muscles supporting the spine. Previous tests have documented its long-term benefits for chronic low back pain.

Who is the study for?
This trial is for adults aged 22 to 75 with chronic low back pain lasting over 90 days despite medical treatment. Participants must have a qualifying pain score, evidence of lumbar muscle dysfunction, and be able to give informed consent and follow the study plan. Exclusions include drug use, certain surgical histories, worse leg than back pain, planned surgeries, BMI over 35, spinal conditions like stenosis or neurological deficits.
What is being tested?
The ReActiv8 Implantable Neurostimulation System is being tested in this trial. It involves two levels of stimulation: low and patient-appropriate. The goal is to assess how safe and effective ReActiv8 is alongside usual medical care for treating chronic lower back pain.
What are the potential side effects?
Potential side effects may include discomfort at the implant site, possible nerve or tissue damage from the implant procedure itself, infection risks associated with surgery or implants, changes in back pain sensation due to stimulation adjustments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 22 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a lower back injury that can be treated with surgery.
Select...
My back pain is caused by issues with my blood vessels.
Select...
I need back surgery according to guidelines or cannot have it for other reasons.
Select...
My back pain is caused by conditions like endometriosis, fibroids, or infections.
Select...
I have a narrow spinal canal in my lower back causing leg pain.
Select...
I have had surgery for scoliosis or currently have scoliosis.
Select...
I have back pain because of spinal cord inflammation or damage.
Select...
I have not had any recent surgeries or procedures.
Select...
My leg pain is worse than my back pain, or I have nerve pain below the knee.
Select...
My BMI is over 35.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative Proportion of Responders Analysis (CPRA) for the Primary Endpoint to Compare Participants Responses Over a Full Range of Response Levels
Mean Change in Low Back Pain VAS
Responder Rate of Low Back Pain With No Increase in Pain Medications
+1 more
Secondary study objectives
Change in European Quality of Life Score on Five Dimensions (EQ-5D)
Change in European Quality of Life Score on Five Dimensions (EQ-5D) at One Year
Change in Oswestry Disability Index (ODI)
+9 more
Other study objectives
Change in Opioid Use for Treatment of Low Back Pain at One-Year
Clinical Global Impression of Change
Clinical Global Impression of Change at One Year
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Group II: ControlExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ReActiv8 Implantable Stimulation System (Low Stimulation)
2016
N/A
~210
ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)
2016
N/A
~210

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Neuromodulation devices, such as spinal cord stimulators and the ReActiv8 system, work by delivering electrical impulses to the spinal cord or peripheral nerves to alter pain signals before they reach the brain, providing significant pain relief. Other common treatments for Chronic Lower Back Pain (CLBP) include NSAIDs and muscle relaxants, which reduce inflammation and muscle spasms, and exercise therapy, which strengthens the muscles supporting the spine and improves flexibility. Understanding these mechanisms helps CLBP patients make informed decisions about their treatment options and manage their expectations regarding pain relief and functional improvement.

Find a Location

Who is running the clinical trial?

Mainstay MedicalLead Sponsor
4 Previous Clinical Trials
431 Total Patients Enrolled
Chris Gilligan, MD, MBAStudy ChairBrigham and Women's Hospital

Media Library

ReActiv8 Implantable Stimulation System (Low Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT02577354 — N/A
Chronic Lower Back Pain Research Study Groups: Treatment, Control
Chronic Lower Back Pain Clinical Trial 2023: ReActiv8 Implantable Stimulation System (Low Stimulation) Highlights & Side Effects. Trial Name: NCT02577354 — N/A
ReActiv8 Implantable Stimulation System (Low Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02577354 — N/A
~22 spots leftby Nov 2025